SCHEDULE: Weiss Asset Management Boosts Theravance Biopharma Stake

Weiss Asset Management LP and its affiliates have increased their beneficial ownership in Theravance Biopharma, Inc. to 14.5% of outstanding shares.

Summary

• Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss collectively report beneficial ownership of 7,457,060 Ordinary Shares of Theravance Biopharma, Inc.
• This represents 14.5% of the Issuer's 51,492,924 outstanding shares as of February 28, 2026, as reported in the Issuer's Form 10-K filed on March 23, 2026.
• BIP GP LLC beneficially owns 4,628,074 shares, representing approximately 9.0% of the outstanding shares.
• Weiss Asset Management LP is the investment manager for both BIP and BGO, which hold the shares.
• Andrew M. Weiss is the managing member of WAM GP LLC and, in such capacity, has the power to vote and dispose of the shares.
• No transactions in the Issuer's shares were effected by the Reporting Persons during the past 60 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as increased institutional ownership by a known entity like Weiss Asset Management can imply a belief in the company's value, though the filing itself is purely informational regarding ownership.

Positives

• Increased stake by an institutional investor like Weiss Asset Management could signal confidence in Theravance Biopharma's long-term value.
• The significant ownership percentage (14.5%) provides Weiss Asset Management with a strong voice in corporate governance matters.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as the 14.5% stake held by Weiss Asset Management, can often signal increased scrutiny on management and strategic direction within the biopharma sector. Such a substantial stake could potentially lead to activist engagement, pushing for operational efficiencies, strategic shifts, or even M&A activities, which is a common dynamic in the industry for companies with promising pipelines or undervalued assets.

Stakeholder Impact

• Shareholders may see increased confidence from a significant institutional investor holding a substantial stake.
• The increased ownership by Weiss Asset Management could potentially lead to future engagement with the company's board and management, influencing strategic decisions.

Key Dates

Keywords

Theravance Biopharma, Weiss Asset Management, Schedule 13D, Beneficial Ownership, Institutional Investor, Biopharma, Equity Stake, G8807B106